DK3129374T3 - (5,6-dihydro) pyrimido [4,5-e] INDOLIZINER - Google Patents

(5,6-dihydro) pyrimido [4,5-e] INDOLIZINER Download PDF

Info

Publication number
DK3129374T3
DK3129374T3 DK15712912.3T DK15712912T DK3129374T3 DK 3129374 T3 DK3129374 T3 DK 3129374T3 DK 15712912 T DK15712912 T DK 15712912T DK 3129374 T3 DK3129374 T3 DK 3129374T3
Authority
DK
Denmark
Prior art keywords
carboxamide
indolizine
dihydropyrimido
anilino
alkyl
Prior art date
Application number
DK15712912.3T
Other languages
Danish (da)
English (en)
Inventor
Man Adrianus Petrus Antonius De
Rogier Christian Buijsman
Jan Gerard Sterrenburg
Joost Cornelis Marinus Uitdehaag
Wit Joeri Johannes Petrus De
Guido Jenny Rudolf Zaman
Original Assignee
Netherlands Translational Res Center B V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Netherlands Translational Res Center B V filed Critical Netherlands Translational Res Center B V
Application granted granted Critical
Publication of DK3129374T3 publication Critical patent/DK3129374T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK15712912.3T 2014-04-07 2015-03-30 (5,6-dihydro) pyrimido [4,5-e] INDOLIZINER DK3129374T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14163734 2014-04-07
EP15153207 2015-01-30
PCT/EP2015/056839 WO2015155042A1 (en) 2014-04-07 2015-03-30 (5,6-dihydro)pyrimido[4,5-e]indolizines

Publications (1)

Publication Number Publication Date
DK3129374T3 true DK3129374T3 (en) 2019-04-08

Family

ID=52774240

Family Applications (1)

Application Number Title Priority Date Filing Date
DK15712912.3T DK3129374T3 (en) 2014-04-07 2015-03-30 (5,6-dihydro) pyrimido [4,5-e] INDOLIZINER

Country Status (16)

Country Link
US (3) USRE50082E1 (en:Method)
EP (1) EP3129374B1 (en:Method)
JP (1) JP6518690B2 (en:Method)
KR (1) KR102432420B1 (en:Method)
CN (1) CN106132963B (en:Method)
AU (1) AU2015243694B2 (en:Method)
BR (1) BR112016022342B1 (en:Method)
CA (1) CA2944610C (en:Method)
DK (1) DK3129374T3 (en:Method)
ES (1) ES2716165T3 (en:Method)
HU (1) HUE043108T2 (en:Method)
MX (1) MX368767B (en:Method)
PL (1) PL3129374T3 (en:Method)
PT (1) PT3129374T (en:Method)
RU (1) RU2692479C2 (en:Method)
WO (1) WO2015155042A1 (en:Method)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106132963B (zh) * 2014-04-07 2019-08-06 荷兰转化研究中心有限责任公司 (5,6-二氢)嘧啶并[4,5-e]吲嗪
ES2966392T3 (es) * 2015-04-17 2024-04-22 Crossfire Oncology Holding B V Biomarcadores pronósticos para quimioterapia inhibidora de TTK
CN109071542B (zh) * 2016-02-19 2021-07-20 凤凰分子设计公司 可用作rsk抑制剂的羧酰胺衍生物
KR20210019607A (ko) 2016-06-07 2021-02-22 자코바이오 파마슈티칼스 컴퍼니 리미티드 Shp2 억제제로서 유용한 신규한 헤테로환형 유도체
CN106551938B (zh) * 2016-11-26 2017-11-24 广东安诺药业股份有限公司 一种治疗非酒精性脂肪肝的药物及其应用
NZ758458A (en) 2017-03-23 2022-07-29 Jacobio Pharmaceuticals Co Ltd Novel heterocyclic derivatives useful as shp2 inhibitors
US20210393623A1 (en) 2018-09-26 2021-12-23 Jacobio Pharmaceuticals Co., Ltd. Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors
JP2022520382A (ja) 2019-02-11 2022-03-30 フェニックス モレキュラー デザインズ Ｒｓｋ阻害剤の結晶形態
US20250049801A1 (en) * 2021-12-15 2025-02-13 Sillajen, Inc. Pharmaceutical combinations for use in the treatment of neoplastic diseases
JP2024544083A (ja) * 2021-12-15 2024-11-27 シルラジェン，インコーポレイテッド 修飾ベータ－シクロデキストリンを含む医薬組成物
JP2024546977A (ja) * 2021-12-15 2024-12-26 シルラジェン，インコーポレイテッド 新生物疾患の処置方法
MX2024010802A (es) * 2022-03-04 2024-09-11 Sillajen Inc Combinaciones farmaceuticas para uso en el tratamiento de enfermedades neoplasicas.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2466243A1 (en) * 2001-09-19 2003-03-27 Aventis Pharma S.A. Indolizines as kinase protein inhibitors
CA2526578C (en) 2003-05-22 2012-01-24 Pharmacia Italia S.P.A. Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
WO2008065054A1 (en) 2006-11-28 2008-06-05 Nerviano Medical Sciences S.R.L. Tricyclic indoles and (4,5-dihydro) indoles
CN102076689B (zh) * 2008-06-26 2014-10-15 内尔维阿诺医学科学有限公司 吡唑并-喹唑啉类
WO2010111406A2 (en) 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
US8586598B2 (en) 2009-04-29 2013-11-19 Nerviano Medical Sciences S.R.L. CDK inhibitor salts
EP2459196B1 (en) 2009-07-29 2015-09-09 Nerviano Medical Sciences S.r.l. Plk inhibitor salts
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
US20130303532A1 (en) 2010-12-17 2013-11-14 Bayer Intellectual Property Gmbh Imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment hyperproliferative disorders
WO2012101032A1 (en) 2011-01-26 2012-08-02 Nerviano Medical Sciences S.R.L. Tricyclic pyrrolo derivatives, process for their preparation and their use as kinase inhibitors
JP6523267B2 (ja) 2013-06-24 2019-05-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｆｓｈｒの調節剤としてのイミダゾール化合物及びその使用
CN106132963B (zh) * 2014-04-07 2019-08-06 荷兰转化研究中心有限责任公司 (5,6-二氢)嘧啶并[4,5-e]吲嗪

Also Published As

Publication number Publication date
CN106132963B (zh) 2019-08-06
US9856258B2 (en) 2018-01-02
JP6518690B2 (ja) 2019-05-22
RU2692479C2 (ru) 2019-06-25
JP2017510595A (ja) 2017-04-13
USRE50082E1 (en) 2024-08-20
KR102432420B1 (ko) 2022-08-17
CA2944610C (en) 2024-01-09
BR112016022342A8 (pt) 2021-07-20
PL3129374T3 (pl) 2019-07-31
BR112016022342A2 (pt) 2017-08-15
BR112016022342B1 (pt) 2022-10-04
CN106132963A (zh) 2016-11-16
RU2016141405A (ru) 2018-05-07
MX368767B (es) 2019-10-15
EP3129374A1 (en) 2017-02-15
ES2716165T3 (es) 2019-06-10
AU2015243694B2 (en) 2019-01-17
PT3129374T (pt) 2019-03-25
EP3129374B1 (en) 2018-12-19
KR20170013866A (ko) 2017-02-07
CA2944610A1 (en) 2015-10-15
HUE043108T2 (hu) 2019-07-29
MX2016012997A (es) 2016-12-07
RU2016141405A3 (en:Method) 2018-10-02
AU2015243694A1 (en) 2016-11-03
US20170096432A1 (en) 2017-04-06
WO2015155042A1 (en) 2015-10-15
USRE48974E1 (en) 2022-03-15

Similar Documents

Publication Publication Date Title
DK3129374T3 (en) (5,6-dihydro) pyrimido [4,5-e] INDOLIZINER
JP6726677B2 (ja) 抗がん剤としての置換２−ｈ−ピラゾール誘導体
AU2016352813B2 (en) Novel pyrazolo pyrimidine derivatives
EP3559000B1 (en) Benzimidazole derivatives, preparation methods and uses theirof
AU2014351413B2 (en) Pyrrolopyrrolone derivatives and their use as BET inhibitors
AU2015407300B2 (en) 2-Arylamino pyridine, pyridine or triazine derivative, preparation method and use thereof
EP3173412B1 (en) 2,4-disubstituted 7h-pyrrolo[2,3-d]pyrimidine derivative, preparation method and medicinal use thereof
CA2791166C (en) Pyrazolopyrimidine compounds and their use as pde10 inhibitors
AU2020255100A1 (en) N-heteroaromatic amide derivatives for treatment of cancer
AU2013344049A1 (en) ALK kinase inhibitors
CN117693503A (zh) 作为hpk1抑制剂用于治疗癌症的经取代的吡嗪-2-甲酰胺
IL322876A (en) A disintegrant containing an aryl substituent for CDK12/13, a method for its preparation, as well as a pharmaceutical composition and medical use thereof
HK1231072A1 (en) (5,6-dihydro)pyrimido[4,5-e]indolizines
HK1231072B (zh) (5，6-二氢)嘧啶并[4，5-e]吲嗪
CN118580220A (zh) 一类细胞周期依赖性蛋白激酶12/13的降解剂，及其制备方法、药物组合物和应用
EA041747B1 (ru) Ингибиторы g12c kras, содержащая их фармацевтическая композиция и использующий их способ лечения рака